<DOC>
	<DOCNO>NCT00301275</DOCNO>
	<brief_summary>Multiple myeloma disorder malignant plasma cell accumulate bone marrow . These plasma cell produce abnormal protein call paraprotein / M spike serum serially monitor assess response tumour therapy . The paraprotein heavy chain either IgG , IgA , IgM IgD light chain either kappa lambda . At present , assessed serum urine electrophoresis ( SPE UPE ) . These technique relatively insensitive poorly quantitative compare immunoassay tumour marker . The potential serum free light chain ( flc ) measurement marker myeloma recognise time . However , development assay prove elusive , primarily due difficulty develop assay convenient use require specificity measure flc serum . Recently , assay standardise use . Its likely assessment flc might sensitive marker document complete remission patient myeloma . The aim study study flc patient myeloma complete remission ( CR ) see patient CR document standard criteria- free light chain still positive good marker remission . The sample collect test batch 60 .</brief_summary>
	<brief_title>Assessing Free Immunoglobulin Light Chains Patients With Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Immunoglobulin Light Chains</mesh_term>
	<criteria>Multiple Myeloma patient CR able give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
</DOC>